The HCV NS3 is considered to be an important target for development of HCV therapeutic vaccines because NS3-specific CD4+ and CD8+ T cell responses correlate well with resolution of the infection [46], [47], [48] and have been described as an indicator for viral clearance both in humans and chimpanzees [48], [49], [50]. This evidence concerns the gene KRAS and infection.